TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results

02 مارس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update

26 فبراير 2021 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology

23 فبراير 2021 07:30:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

05 فبراير 2021 13:54:45 بحسب Nasdaq GlobeNewswire

TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference

15 يناير 2021 07:00:00 بحسب Nasdaq GlobeNewswire

TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

08 يناير 2021 07:00:00 بحسب Nasdaq GlobeNewswire